HC Wainwright & Co. Maintains Buy on Edgewise Therapeutics, Raises Price Target to $57

HC Wainwright & Co. analyst Lander Egaña Gorroño has maintained a Buy rating on Edgewise Therapeutics (NASDAQ: EWTX) and increased the price target from $45 to $57.